Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05545891
PHASE2

Aripiprazole in Body Focused Repetitive Behaviors

Sponsor: University of Chicago

View on ClinicalTrials.gov

Summary

This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for the remaining three weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either aripiprazole or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.

Official title: A Double-Blind, Placebo Controlled Study of Aripiprazole in Body Focused Repetitive Behaviors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2026-06

Completion Date

2027-12

Last Updated

2025-10-02

Healthy Volunteers

No

Interventions

DRUG

Placebo

A drug that contains no medicine

DRUG

Aripiprazole

Atypical antipsychotic medication

Locations (1)

University of Chicago

Chicago, Illinois, United States